All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View MPN content recommended for you
Real-world ruxolitinib in MF: A multicenter Japanese study
Results from a multicenter, observational study evaluating long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis (MF; N = 892) in Japan were recently published in Future Oncology by Aruga et al.
Key data: Adverse drug reactions (ADRs) occurred in 67.7% of patients; the most common were anemia (27.8%) and decreased platelet count (21.4%). At 6 months, spleen response (complete disappearance or ≥50% reduction) and symptom improvement were observed in 26.2% and 52.0% of patients, respectively. Median overall survival (OS) was not reached, with estimated survival rates of 92.2%, 87.1%, 78.4%, and 71.8% at 182, 364, 728, and 1,092 days, respectively.
Key learning: In real-world clinical settings in Japan, ruxolitinib demonstrated effectiveness in reducing spleen size and improving symptoms in patients with MF, with no new safety concerns compared with clinical trial data.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
A 68-year-old male with primary myelofibrosis received ruxolitinib 10 mg twice daily for 7 months. His spleen size and symptoms are controlled, but Hb remains <8 g/dL. EPO, 210 mU/mL; platelets, 85,000/µL. What is your next step?
